News ArticleNeuland Laboratories Reports Rs. 47.1 Crores Land Acquisition and Unaudited Q2 FY2026 Financial Results
Company records Rs. 1,10,722.10 lakhs total income for half year ended September 30, 2026 and plans capacity expansion financed from internal accruals
Neuland Laboratories Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company reported total income of Rs. 1,10,722.10 lakhs for H1 FY2026. Additionally, Neuland approved a capital expenditure of Rs. 47.1 crores for acquiring a land parcel in Telangana to support future capacity expansion, financed through internal accruals.
Neuland Laboratories Limited
Investor Presentation
Neuland Laboratories Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, alongside approving a Rs. 47.1 crores capital expenditure for land acquisition in Telangana aimed at future capacity expansion.
For the half year ended September 30, 2026, the company reported total income of Rs. 1,10,722.10 lakhs, including Rs. 1,09,123.40 lakhs from operations and Rs. 1,598.70 lakhs from other income.
The board approved the acquisition of approximately 6 acres of land in Domadugu Village, Sangareddy District, Telangana for Rs. 47.1 crores including GST, financed through internal accruals.
The land purchase is intended to support future capacity expansions, although no immediate capacity addition or utilization figures were reported.
The financial results have been reviewed by the statutory auditors in accordance with applicable Indian accounting standards.
The board meeting started at 9:30 a.m. and concluded at 3:34 p.m. on November 3, 2026, with the outcomes disclosed to stock exchanges and published on the company's website.
Highlights
- Total income for H1 FY2026 at Rs. 1,10,722.10 lakhs.
- Capital expenditure of Rs. 47.1 crores approved for land acquisition in Telangana.
- Land parcel size: approximately 6 acres in Domadugu Village.
- Funding for land acquisition through internal accruals.
- Board meeting held on November 3, 2026, approved results and capital expenditure.
Key Data Snapshot
What happened
- Neuland Laboratories announced unaudited standalone and consolidated financial results for quarter and half year ended September 30, 2026.
- Total income for the half year period was Rs. 1,10,722.10 lakhs.
- Board approved capital expenditure of Rs. 47.1 crores to acquire land in Telangana for capacity expansion.
- The land parcel measures approximately 6 acres in Domadugu Village, Sangareddy District.
- Funding for the acquisition will be through internal accruals.
Key details
- No existing capacity or capacity utilization reported related to the land acquisition as it is for future expansion.
- No immediate capacity addition planned at the time of announcement.
- Financial results are prepared in compliance with Indian Accounting Standard 34 (Ind AS 34).
- Results reviewed by statutory auditors with a limited review report.
- Subsidiaries' financials included in consolidated results though some interim information is unaudited.
Regulatory and governance context
- Announcement made pursuant to SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
- Scrip codes: BSE - 524558, NSE - NEULANDLAB.
- Results and board decisions published on company's official website.
- Board meeting held from 9:30 a.m. to 3:34 p.m. on November 3, 2026.
Highlights
- Total income for H1 FY2026 at Rs. 1,10,722.10 lakhs.
- Capital expenditure of Rs. 47.1 crores approved for land acquisition in Telangana.
- Land parcel size: approximately 6 acres in Domadugu Village.
- Funding for land acquisition through internal accruals.
- Board meeting held on November 3, 2026, approved results and capital expenditure.
Disclosures
- SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
- Ind AS 34 - Interim Financial Reporting
More News on Investor Presentation
View allLatest corporate announcements and market updates in Investor Presentation.
Multi Commodity Exchange of India Ltd Reports Nearly 100% Increase in Total Income for H1 FY27 with ₹1,603 Crore
Multi Commodity Exchange of India Ltd (MCX) reported total income of ₹1,603 crore for the half year ended September 30, 2026, nearly doubling the ₹807 crore recorded in the same period last year. Profit after tax reached ₹868 crore, showcasing substantial financial growth.
Read Full Story
GlaxoSmithKline India Achieves 21% Revenue Growth in Q2 FY27 with Innovation-Driven Portfolio Expansion
GlaxoSmithKline Pharmaceuticals Limited reported a 21% revenue increase to ₹1180 crore in Q2 FY27, driven by strong sales execution and a rising contribution from its innovation portfolio which grew to 7% of total sales. The company sustained market leadership with a 25% share in its representative market amid competitive industry growth.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 mn Revenue in Q2 FY27 with 29% YoY Growth Bolstered by India Formulations
Zydus Lifesciences Limited recorded a 29% year-on-year increase in revenues to Rs. 79,096 million during the second quarter of fiscal year 2027, driven primarily by robust growth in their India branded formulations and North America markets.
Read Full Story
